Sirolimus is Associated with New-onset Diabetes in Kidney Transplant Recipients

Overview

Journal J Am Soc Nephrol

Specialty Nephrology

Date 2008 Apr 4

PMID 18385422

Citations 144

Authors

Olwyn Johnston

Caren L Rose

Angela C Webster

John S Gill

Affiliations

Soon will be listed here.

Abstract

New-onset diabetes (NOD) is associated with transplant failure. A few single-center studies have suggested that sirolimus is associated with NOD, but this is not well established. With the use of data from the United States Renal Data System, this study evaluated the association between sirolimus use at the time of transplantation and NOD among 20,124 adult recipients of a first kidney transplant without diabetes. Compared with patients treated with cyclosporine and either mycophenolate mofetil orazathioprine, sirolimus-treated patients were at increased risk for NOD, whether it was used in combination with cyclosporine (adjusted hazard ratio [HR] 1.61; 95% confidence interval [CI] 1.36 to 1.90),tacrolimus (adjusted HR 1.66; 95% CI 1.42 to 1.93), or an antimetabolite (mycophenolate mofetil orazathioprine; adjusted HR 1.36; 95% CI 1.09 to 1.69). Similar results were obtained in a subgroup analysis that included the 16,861 patients who did not have their immunosuppressive regimen changed throughout the first posttransplantation year. In conclusion, sirolimus is independently associated with NOD. Given the negative impact of NOD on posttransplantation outcomes, these findings should be confirmed in prospective studies or in meta-analyses of existing trials that involved sirolimus.

Citing Articles

New Onset Diabetes After Organ Transplantation: Risk Factors, Treatment, and Consequences.

Popovic L, Bulum T Diagnostics (Basel). 2025; 15(3).

PMID: 39941214 PMC: 11816453. DOI: 10.3390/diagnostics15030284.

Severe Hypertriglyceridemia in a Patient Treated With Sirolimus for Graft-vs-Host Disease Prophylaxis.

Criner K, Student J, Arkin J, Carp J, Sokoloff S JCEM Case Rep. 2024; 2(11):luae193.

PMID: 39498472 PMC: 11532646. DOI: 10.1210/jcemcr/luae193.

The translation initiation factor eIF2α regulates lipid homeostasis and metabolic aging.

Huang H, Liao Y, Li N, Qu X, Li C, Hou J Aging Cell. 2024; 24(1):e14348.

PMID: 39407444 PMC: 11709108. DOI: 10.1111/acel.14348.

Posttransplant complications: molecular mechanisms and therapeutic interventions.

Liu X, Shen J, Yan H, Hu J, Liao G, Liu D MedComm (2020). 2024; 5(9):e669.

PMID: 39224537 PMC: 11366828. DOI: 10.1002/mco2.669.

New-Onset Diabetes Mellitus after Kidney Transplantation.

Alajous S, Budhiraja P J Clin Med. 2024; 13(7).

PMID: 38610694 PMC: 11012473. DOI: 10.3390/jcm13071928.

References

Hricik D, Anton H, Knauss T, Rodriguez V, Seaman D, Siegel C . Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. Transplantation. 2002; 74(2):189-93. DOI: 10.1097/00007890-200207270-00008. View

DAVID D, Cheigh J, Braun Jr D, Fotino M, STENZEL K, RUBIN A . HLA-A28 and steroid-induced diabetes in renal transplant patients. JAMA. 1980; 243(6):532-3. View

Kuypers D . Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf. 2005; 28(2):153-81. DOI: 10.2165/00002018-200528020-00006. View

McBean A, Li S, Gilbertson D, Collins A . Differences in diabetes prevalence, incidence, and mortality among the elderly of four racial/ethnic groups: whites, blacks, hispanics, and asians. Diabetes Care. 2004; 27(10):2317-24. DOI: 10.2337/diacare.27.10.2317. View

Rector T, Wickstrom S, Shah M, Thomas Greeenlee N, Rheault P, Rogowski J . Specificity and sensitivity of claims-based algorithms for identifying members of Medicare+Choice health plans that have chronic medical conditions. Health Serv Res. 2004; 39(6 Pt 1):1839-57. PMC: 1361101. DOI: 10.1111/j.1475-6773.2004.00321.x. View

Burroughs T, Lentine K, Takemoto S, Swindle J, Machnicki G, Hardinger K . Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new-onset diabetes. Clin J Am Soc Nephrol. 2007; 2(3):517-23. DOI: 10.2215/CJN.00620206. View

Arner P, Gunnarsson R, Blomdahl S, Groth C . Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care. 1983; 6(1):23-5. DOI: 10.2337/diacare.6.1.23. View

Bloom R, Rao V, Weng F, Grossman R, Cohen D, Mange K . Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol. 2002; 13(5):1374-80. DOI: 10.1097/01.asn.0000012382.97168.e0. View

Kwon G, Marshall C, Liu H, Pappan K, Remedi M, McDaniel M . Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels: effects on cell cycle progression in rodent islets. J Biol Chem. 2005; 281(6):3261-7. DOI: 10.1074/jbc.M508821200. View

10.

Mittelman S, Bergman R . Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin. Am J Physiol Endocrinol Metab. 2000; 279(3):E630-7. DOI: 10.1152/ajpendo.2000.279.3.E630. View

11.

Romagnoli J, Citterio F, Nanni G, Favi E, Tondolo V, Spagnoletti G . Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transplant Proc. 2006; 38(4):1034-6. DOI: 10.1016/j.transproceed.2006.03.072. View

12.

Reisaeter A, Hartmann A . Risk factors and incidence of posttransplant diabetes mellitus. Transplant Proc. 2001; 33(5A Suppl):8S-18S. DOI: 10.1016/s0041-1345(01)02229-1. View

13.

Cosio F, Pesavento T, Osei K, Henry M, Ferguson R . Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int. 2001; 59(2):732-7. DOI: 10.1046/j.1523-1755.2001.059002732.x. View

14.

Knoll G, Bell R . Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ. 1999; 318(7191):1104-7. PMC: 27842. DOI: 10.1136/bmj.318.7191.1104. View

15.

Syed N, Khandelwal R . Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells. Mol Cell Biochem. 2000; 211(1-2):123-36. DOI: 10.1023/a:1007159422667. View

16.

Roth D, Milgrom M, Esquenazi V, Fuller L, Burke G, Miller J . Posttransplant hyperglycemia. Increased incidence in cyclosporine-treated renal allograft recipients. Transplantation. 1989; 47(2):278-81. View

17.

Boudreaux J, McHugh L, Canafax D, Ascher N, Sutherland D, Payne W . The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation. 1987; 44(3):376-81. DOI: 10.1097/00007890-198709000-00010. View

18.

Hay N, Sonenberg N . Upstream and downstream of mTOR. Genes Dev. 2004; 18(16):1926-45. DOI: 10.1101/gad.1212704. View

19.

Pirsch J, Miller J, Deierhoi M, Vincenti F, Filo R . A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation. 1997; 63(7):977-83. DOI: 10.1097/00007890-199704150-00013. View

20.

Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol J . Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007; 7(6):1506-14. DOI: 10.1111/j.1600-6143.2007.01749.x. View